Susan E. Morano - Jul 3, 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: Director
Signature: /s/ Susan Thompson, Attorney-in-Fact
Stock symbol: BSX
Transactions as of: Jul 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 7/6/2023, 04:57 PM
Previous filing: Jun 30, 2023
Next filing: May 13, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BSX	Common Stock	Award	$0	+1.63K		$0.00	1.63K	Jul 3, 2023	Direct	F1
transaction	BSX	Common Stock	Award	$0	+456	+28.04%	$0.00	2.08K	Jul 3, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Deferred Stock Units	Award	$0	+1.63K		$0.00	1.63K	Jul 3, 2023	Common Stock	1.63K		Direct	F3, F4
transaction	BSX	Deferred Stock Units	Award	$0	+456	+28.04%	$0.00	2.08K	Jul 3, 2023	Common Stock	456		Direct	F3, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of common stock on the date of grant.
F2	Grant of restricted stock in lieu of 25% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. Reflects a value of approximately $24,428.88 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant.
F3	Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4	Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
F5	Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,428.87 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.